Stereotaxis Inc (STXS) (Q3 2026) Earnings Call Highlights: Revenue Jumps 20% on GenesisX and ...
Stereotaxis, Inc. Q3 2026 Earnings Call Summary
TD Cowen Maintains Buy on Stereotaxis, Lowers Price Target to $2
What Stereotaxis (STXS) Said on Its Q3 Earnings Call
Stereotaxis (STXS) Q3 2026 Earnings Call Transcript
Stereotaxis, Inc. (STXS) Q3 2026 Earnings Call Transcript
Stereotaxis Reports 2026 Third Quarter Financial Results & Business Updates
Stereotaxis Announces Convertible Note Financing of Up To $24 Million
Stereotaxis Q3 2026 Earnings Call Transcript
Stereotaxis Announces Up To $24M Convertible Note Financing; $12M Initial Funding Plus $12M Milestone-Based Availability
Stereotaxis Q3 EPS $(0.07) Misses $(0.05) Estimate, Sales $8.925M Miss $9.600M Estimate
First-in-Human Coronary Intervention Study Results of Robocath’s Next-Generation Robotic System Highlighted at TCT
Stereotaxis Announces 100% Clinical Success Rate For Its Robocath's Robotic System At Transcatheter Cardiovascular Therapeutics Conference; Technical Success Reported At 95%
Stereotaxis Announces First Robotic Magnetic Navigation System in Latvia
Stereotaxis Says Pauls Stradiņš Clinical University Hospital In Latvia, Establishes Robotic Center For Treatment Of Cardiac Arrhythmias In Latvia And Treats Initial Patients With Genesis Robotic Magnetic Navigation System
Stereotaxis to Report Third Quarter 2026 Financial Results on November 10, 2026
Stereotaxis Emerging Digital, AI and Automation Capabilities to be Featured at Heart Rhythm Society’s HRX 2026
Stereotaxis: A Real Product Story, But The Stock Already Prices In Success
University of Szeged Celebrates Strongest First Month of Robotic Cardiology Program
Stereotaxis Secures FDA 510(k) Clearance For GenesisX Robotic Magnetic Navigation System
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.